China accepted the drug registration application of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) units Yaopharma and Jisimei (Wuhan) Pharmaceutical for their injectables, according to a Monday filing with the Hong Kong Exchange.
Yaopharma is the manufacturer of levofloxacin injection for mild, moderate, and severe bacterial infections such as hospital and community-acquired pneumonia, and other infections, the filing said.
Jisimei (Wuhan) Pharmaceutical manufactures cytarabine injection for acute myelogenous leukemia and other types of leukemia, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments